LLY · News · 20261114N

GLP-1 Pricing and Payer Economics

ELI LILLY & Co · 2026-11-14 · Importance 20 · Surprise 24

A CVS Health analysis of Aetna claims found that GLP-1 medications for weight loss and diabetes could generate net savings for payors, including employers and plan sponsors, if priced below $350 per month. The analysis covered patients who had recently started taking the drugs and linked savings to reduced use of other health care services. Lilly markets Zepbound (tirzepatide) for obesity and Mounjaro (tirzepatide) for type 2 diabetes; the report also identifies Novo Nordisk’s Wegovy and Ozempic as competing products.

Key facts